AR and prostate cancer: To test this, we investigated the distribution of AR sites in previously published ChIP‐seq datasets from benign prostate tissues, primary prostate cancers [10] and cell lines (LNCaP and VCaP [42, 43] and in mCRPC patient‐derived xenografts (PDX) [18].